Saharsh Davuluri, Joint Managing Director, Neuland Labs01.26.17
Contract service providers need to continuously adapt to and stay ahead of the evolving needs and demands of the pharmaceutical and biotechnology industries. This is especially true for contract manufacturing organizations (CMOs), which in recent years have witnessed important ongoing changes in the key industry players and across the pipelines of Big Pharma and smaller biopharmaceutical companies alike. Other factors contributing to the shifting landscape CMOs face include innovation in drug development leading to increasingly complex chemical entities, advances in technology and techniques, and increasingly stringent regulatory requirements facing drug manufacturers.
These evolving and emerging factors represent both challenges and opportunities for CMOs, and this important duality should not be overlooked. Meeting these challenges and taking advantage of these opportunities are critical not just for the survival of a CMO, but also for its growth and ability to thrive in this highly competitive environment.
Outsourcing of API manufacturing
According to the results of a small molecule outsourcing surve
These evolving and emerging factors represent both challenges and opportunities for CMOs, and this important duality should not be overlooked. Meeting these challenges and taking advantage of these opportunities are critical not just for the survival of a CMO, but also for its growth and ability to thrive in this highly competitive environment.
Outsourcing of API manufacturing
According to the results of a small molecule outsourcing surve
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
